Govt holds scientific conclave to boost pharma quality compliance
New Delhi, June 11
A scientific conclave and interactive session on the Indian Pharmacopoeia 2026 was held in Haridwar to raise awareness of new provisions under IP and promote quality compliance across the pharmaceutical manufacturing sector, the government said on Thursday.
Indian Pharmacopoeia Commission (IPC), an autonomous institution under the Ministry of Health and Family Welfare, organised the conclave, in collaboration with the Association of Devbhumi Pharma Industries and affiliated Uttarakhand pharmaceutical associations.
The event brought together manufacturers, quality control and assurance professionals, regulatory authorities, analytical scientists and drug testing laboratory personnel to discuss recent developments in pharmacopoeial standards and their implementation in the pharmaceutical industry.
Uttarakhand is one of India's leading pharmaceutical manufacturing hubs and has been among the states effectively utilising the IP and Indian Pharmacopoeia Reference Substances for ensuring the quality, safety, and efficacy of medicines.
The conclave was organised in the state to further strengthen industry awareness, support compliance with pharmacopoeial requirements, and promote the consistent adoption of IP standards across the pharmaceutical sector, thereby providing handholding support to pharmaceutical manufacturers and other stakeholders in the state.
Dr V Kalaiselvan, Secretary‑cum‑Scientific Director, IPC, underscored the role of the IP in establishing scientifically validated quality standards for medicines and supporting India's growing stature as a global pharmaceutical leader.
He highlighted the key advancements incorporated in IP 2026 and stressed industry participation in ensuring the effective implementation of pharmacopoeial requirements.
Technical deliberations and knowledge-sharing interactions were conducted on key aspects of the IP, including recent developments in pharmacopoeial standards, reference substances, microbiological quality requirements, quality management systems, analytical investigations and biological standards.
The sessions provided participants with practical insights into the application of IP standards in pharmaceutical manufacturing and quality control.
The event concluded with a networking session, enabling continued dialogue among regulators, industry representatives, and scientific experts on advancing pharmaceutical quality and compliance in Uttarakhand and across the country.
— IANS
Reader Comments
It's encouraging to see India taking pharmaceutical quality so seriously. With India being the "pharmacy of the world," these scientific conclaves are crucial for maintaining global trust. The emphasis on reference substances and microbiological quality is spot-on. Hope this translates into tangible improvements in manufacturing practices.
Nice to see government focusing on quality compliance. But let's be honest - these conclaves often remain in conference rooms while on-ground implementation remains weak. I work in a pharma unit in Uttarakhand and many workers don't even know about IP 2026. Need more practical workshops, not just presentations. 🙏
As someone who imports Indian generic medicines, this is reassuring. Consistent quality standards benefit everyone - patients, doctors, and the industry. The collaborative approach with local pharma associations is smart. I'd like to see more international experts involved in future conclaves for cross-learning.
Finally, some concrete steps towards pharma quality! My family relies on Indian medicines and we've had concerns about quality consistency. But I wish these events also addressed the shortage of qualified quality control professionals in smaller towns. Without skilled manpower, even the best standards remain on paper.
Great step forward for India's pharma sector! The focus on IP 2026 and reference substances is much needed. However, I hope the government also strengthens the regulatory enforcement aspect - mere awareness isn't enough. Stringent inspections and penalties for non-compliance should accompany such initiatives. Jay Hind! 🇮🇳
We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.